Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2 × HER2 × HER3 T-Body
- Development stage
- Preclinical
- Lead developer
- Invenra
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HER2 × HER2 × HER3 T-Body is a preclinical-stage trispecific antibody-drug conjugate (ADC) developed by Invenra. Built on Invenra's proprietary T-Body trispecific platform, the molecule features a biparatopic design targeting two distinct epitopes on human epidermal growth factor receptor 2 (HER2) alongside a third binding arm targeting human epidermal growth factor receptor 3 (HER3). This trispecific configuration is engineered to trigger a HYPER-Internalization mechanism, which dramatically enhances receptor internalization and payload delivery into cancer cells. Preclinical studies have demonstrated that this approach effectively kills tumor cells across HER2-high, HER2-low, and triple-negative breast cancer lines, offering a potential strategy to overcome resistance to conventional HER2-targeted therapies.
- Other names
- HER2 x HER2 x HER3 T-BodyHER-2 x HER2 x HER3 T-BodyHER 2 x HER2 x HER3 T-BodyHER2 × HER2 × HER3 T-Body ADCHER2 × HER2 × HER3 T-Body trispecific ADCHER2 × HER2 × HER3 T-Body trispecific antibody
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2 × HER2 × HER3 T-Body.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2 × HER2 × HER3 T-Body.